[Geroprotective drugs - mTOR inhibitors in the treatment of cancer patients.].

The review describes the experimental and clinical data of the last decades on the use of geroprotective preparations of mTOR inhibitors group for the main and accompanying treatment of cancer patients. mTOR protein kinase is an perspective therapeutic target for the treatment of multiple cancers, both with the mTOR inhibitors themselves (rapamycin and its derivatives) and in combination with inhibitors of other pathways (for example, metformin). The mTOR inhibitors, not being classical cytostatics and not having carcinogenic activity, have great prospects for use both as independent antitumor agents and for use in combination with conventional chemotherapy.